Home Companies Catalysts Deep Dives
Rybelsus semaglutide APPROVED
Drug Profile
ModalityPeptide
RouteORAL
Therapy AreaCVRM
Launch2019-09-20
Peak Sales Est$5000M
Formulations[{"id":"rybelsus-oral","doses":"3mg, 7mg, 14mg","route":"ORAL","setting":"PATIENT_SELF","frequency":
Companies
NVO (ORIGINATOR)100%
Mechanism: GLP-1 receptor agonist
Expert: Glucagon-like peptide-1 receptor agonist that enhances glucose-dependent insulin secretion, suppresses glucagon, delays gastric emptying, and reduces appetite via hypothalamic signaling.
Everyday: Mimics a gut hormone that reduces appetite and helps control blood sugar by signaling fullness to the brain.
Targets: ["GLP-1R"]
Revenue History
PeriodRevenue ($M)
2025$4,200M
Q4 2025$1,150M
Programs (1)
IndicationStageKey StudyRegional Status
Type 2 DiabetesAPPROVEDPIONEER 1-10[{"stage":"APPROVED","region":"US","approval_date":"2019-09-20"},{"stage":"APPRO
Data from Supabase · Updated 2026-03-24